​
​

Atossa Therapeutics (ATOS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ATOS Stock Forecast

Atossa Therapeutics stock forecast is as follows: an average price target of $5.00 (represents a 290.63% upside from ATOS’s last price of $1.28) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

ATOS Price Target

The average price target for Atossa Therapeutics (ATOS) is $5.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 290.63% upside from ATOS's last price of $1.28.

ATOS Analyst Ratings

Buy

According to 3 Wall Street analysts, Atossa Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ATOS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Atossa Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 08, 2023Louise ChenCantor Fitzgerald$5.00$0.83499.81%290.63%
Row per page
Go to

The latest Atossa Therapeutics stock forecast, released on Sep 08, 2023 by Louise Chen from Cantor Fitzgerald, set a price target of $5.00, which represents a 499.81% increase from the stock price at the time of the forecast ($0.83), and a 290.63% increase from ATOS last price ($1.28).

Atossa Therapeutics Price Target by Period

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.28$1.28$1.28
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Atossa Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Atossa Therapeutics's last price of $1.28. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 11, 2024AscendiantBuyBuyHold
Jul 01, 2024H.C. WainwrightBuyBuyHold
May 13, 2024H.C. WainwrightBuyBuyHold
Sep 08, 2023Cantor Fitzgerald-OverweightInitialise
Row per page
Go to

Atossa Therapeutics's last stock rating was published by Ascendiant on Sep 11, 2024. The company gave ATOS a "Buy" rating, the same as its previous rate.

Atossa Therapeutics Financial Forecast

Atossa Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 14Mar 13
Revenue-------$24.12K$182.67K
Avg Forecast-------$22.00K$128.57K
High Forecast-------$26.40K$154.28K
Low Forecast-------$17.60K$102.86K
# Analysts-------98
Surprise %-------1.10%1.42%

Atossa Therapeutics's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. ATOS's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $24.12K (Mar 14).

Atossa Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 14Mar 13
# Analysts-------98
EBITDA-------$-2.29M$-1.84M
Avg Forecast-------$-2.49M$-1.11M
High Forecast-------$-1.99M$-884.39K
Low Forecast-------$-2.99M$-1.33M
Surprise %-------0.92%1.67%

undefined analysts predict ATOS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Atossa Therapeutics's previous annual EBITDA (undefined) of $NaN.

Atossa Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 14Mar 13
# Analysts-------98
Net Income-------$-2.41M$-1.94M
Avg Forecast$-7.55M$-7.55M$-7.55M$-7.55M$-7.55M$-7.55M$-7.54M$-2.63M$-1.16M
High Forecast$-7.55M$-7.55M$-7.55M$-7.55M$-7.55M$-7.55M$-7.54M$-2.10M$-931.89K
Low Forecast$-7.55M$-7.55M$-7.55M$-7.55M$-7.55M$-7.55M$-7.54M$-3.16M$-1.40M
Surprise %-------0.92%1.67%

Atossa Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ATOS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Atossa Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 14Mar 13
# Analysts-------98
SG&A-------$2.01M$1.84M
Avg Forecast---------
High Forecast---------
Low Forecast---------
Surprise %---------

Atossa Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ATOS last annual SG&A of $2.01M (Mar 14).

Atossa Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 14Mar 13
# Analysts-------98
EPS-------$-17.78$-26.04
Avg Forecast$-0.06$-0.06$-0.06$-0.06$-0.06$-0.06$-0.06$-21.60$-10.80
High Forecast$-0.06$-0.06$-0.06$-0.06$-0.06$-0.06$-0.06$-17.28$-8.64
Low Forecast$-0.06$-0.06$-0.06$-0.06$-0.06$-0.06$-0.06$-25.92$-12.96
Surprise %-------0.82%2.41%

According to undefined Wall Street analysts, Atossa Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ATOS previous annual EPS of $NaN (undefined).

Atossa Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ELEVElevation Oncology$0.58$9.001451.72%Buy
ONTXTraws Pharma$1.00$7.00600.00%Buy
NVAXNovavax$8.00$50.80535.00%Buy
OCGNOcugen$0.87$5.00474.71%Buy
INOInovio Pharmaceuticals$4.03$22.67462.53%Hold
ATOSAtossa Therapeutics$1.28$5.00290.63%Buy
VXRTVaxart$0.62$2.00222.58%Hold
GOVXGeoVax Labs$2.91$8.00174.91%Buy
PALIPalisade Bio$2.43$1.50-38.27%Buy

ATOS Forecast FAQ

Is Atossa Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Atossa Therapeutics (ATOS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of ATOS's total ratings.

What is ATOS's price target?

Atossa Therapeutics (ATOS) average price target is $5 with a range of $5 to $5, implying a 290.62% from its last price of $1.28. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Atossa Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ATOS stock, the company can go up by 290.62% (from the last price of $1.28 to the average price target of $5), up by 290.62% based on the highest stock price target, and up by 290.62% based on the lowest stock price target.

Can Atossa Therapeutics stock reach $2?

ATOS's average twelve months analyst stock price target of $5 supports the claim that Atossa Therapeutics can reach $2 in the near future.

What are Atossa Therapeutics's analysts' financial forecasts?

Atossa Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-22.637M (high $-22.637M, low $-22.637M), average SG&A $0 (high $0, low $0), and average EPS is $-0.18 (high $-0.18, low $-0.18). ATOS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-30.185M (high $-30.185M, low $-30.185M), average SG&A $0 (high $0, low $0), and average EPS is $-0.24 (high $-0.24, low $-0.24).

Did the ATOS's actual financial results beat the analysts' financial forecasts?

In terms of the last quarterly report (Mar 2014), Atossa Therapeutics's revenue was $24.12K, beating the average analysts' forecast of $22K by 9.65%. The company's EBITDA was $-2.286M, missing the average prediction of $-2.493M by -8.33%. Atossa Therapeutics's net income was $-2.412M, missing the average estimation of $-2.631M by -8.31%. The company's SG&A was $2.01M, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $-17.78, missing the average prediction of $-21.6 by -17.69%